ClinicalTrials.gg
RecruitingNCT07490912Neo-LifeUpdated Mar 24, 2026

Neonatal Data and Biobank to Study Factors Influencing Development in Preterm Infants Born at <32 Weeks' Gestation and/or <1500 g Birth Weight

An observational study in Preterm Infant Development, Preterm Infant Health and Prematurity Complications, sponsored by University Hospital of Cologne. Recruiting at 1 site in Germany. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by University Hospital of Cologne · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,300
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Premature Birth with a site in Germany — 11 open to participants now, 13 under way, 1 of them phase 3. Premature Birth · Germany.

Planned enrollment
5th of 28
1,300 · median 225
Started
2026
the only one that year
Observational
28 of 68
7 open now
Primary completion
2036-03
later than 12 of 12 live
Registered
68th of 68
by date
Lead sponsor
3 of 68
University Hospital of Cologne

Among the 68 studies in Premature Birth with a site in Germany, this one is the 5th largest by planned enrollment of the 28 observational ones that give a count, is the only one that started in 2026, is one of 28 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 68th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

11 of the 68 studies in Premature Birth with a site in Germany are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Premature Birth with a site in Germany, or all of them as a file.
02

Study summary

The Neo-Life project aims to establish a prospective neonatal data and biobank to investigate factors influencing the short- and long-term development of very preterm infants. Advances in neonatal care have significantly improved survival rates of infants born with a gestational age of less than 32 weeks and/or a birth weight below 1500 g. However, these infants remain at high risk for multiple complications affecting neurological, pulmonary, cardiovascular, renal, and other organ systems, which may lead to long-term morbidity and reduced quality of life. Identifying early risk and protective factors is therefore essential to improve outcomes and develop targeted interventions.

The primary objective of the project is the prospective and structured collection of clinical data as well as biological samples within a standardized interdisciplinary follow-up program for preterm infants. The study aims to identify biological, clinical, and environmental factors associated with the development and long-term outcomes of different organ systems.

The study population includes infants born with a gestational age of less than 32 weeks and/or a birth weight below 1500 g who receive care at the perinatal center of the University Hospital Cologne. Participation requires informed consent from the parents or legal guardians. There are no specific exclusion criteria. Participants will be followed within the established preterm follow-up program over several years, allowing longitudinal assessment of clinical outcomes and developmental trajectories. Primary outcome is survival without impairment (e.g. neurocognitive, pulmonal, cardiovascular, renal) at the age of 5 years. Secondary outcomes include duration of breastfeeding, nutritional status, body mass index, and parental stress and bonding. In addition, biological samples will be collected to enable the creation of epigenetic, gene expression, and cytokine profiles. These data will contribute to the identification of predictive biomarkers that may help stratify risk and guide individualized preventive or therapeutic strategies in preterm infants.

By combining comprehensive clinical data with biological samples in a dedicated data and biobank, the Neo-Life project aims to generate a valuable resource for translational research. The findings are expected to improve understanding of the mechanisms underlying organ development and long-term health in preterm infants and to support the development of early interventions that may prevent or mitigate adverse outcomes.

03

Conditions studied

  • Preterm Infant Development
  • Preterm Infant Health
  • Prematurity Complications
  • Premature Birth

Browse trials for

Keywords

  • prematurity
  • preterm infants
  • very low birth weight infants
  • very preterm infants
  • gestational age <32 weeks
  • Premature birth
  • <32 weeks gestational age
  • very low birth weight
  • <1500 g birth weight
  • database
  • biobank
  • preterm infant development
  • preterm infant health
  • preterm infant long-term outcome
  • prematurity complications
  • risk and protective factors of preterm infant development
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants born with a gestational age of less than 32 weeks and/or a birth weight below 1500 g who receive care at the perinatal center of the University Hospital Cologne

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born \<32 weeks' gestational age and/or with a birth weight \< 1500 g
  • of parents/ legal guardians

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,300 participants (estimated)
Target follow-up
18 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Preterm infants <32 weeks' GA and/or <1500 BW

    Preterm infants born \<32 weeks' gestational age and/or with a birth weight \<1500 g who receive care at the perinatal center of the University Hospital Cologne.

06

What researchers measure

Primary outcomes

  1. Survival without cognitive impairment

    Neurocognitive Impairment is defined as Bayley Scales of Infant Development III (Bayley - III) cognitive score less than 84.

    Time frame: at the age of 5 years

  2. Survival without impaired motor function

    Motor function impairment is defined as Gross Motor Function Classification System (GMFCS) level of 2 or higher.

    Time frame: at the age of 5 years

  3. Survival without visual impairment

    Visual impairment is defined as need of visual aid or blindness.

    Time frame: at the age of 5 years

  4. Survival without hearing impairment

    Hearing impairment is defined as hearing with amplification or hearing loss despite amplification.

    Time frame: at the age of 5 years

  5. Survival without seizures

    The occurrence of seizures is assessed during follow-up visits.

    Time frame: at the age of 5 years

Secondary outcomes

  1. Duration of breast feeding

    Duration of breast feeding is assessed during follow-up visits.

    Time frame: 2 years

  2. Weight gain

    Weight progression is assessed using percentile curves (Fenton, WHO). This includes assessing wether the weight trajectory lies within the normal range (10th - 90th percentile) and wether percentile shifts occur.

    Time frame: birth to the age of 18 years

  3. Growth in length/height

    Growth in length/height is assessed using percentile curves (Fenton, WHO). This includes assessing wether the length/height trajectory lies within the normal range (10th - 90th percentile) and wether percentile shifts occur.

    Time frame: birth to the age of 18 years

  4. General Movements

    Early infant development will be assessed using General Movements Assessment by Prechtl. It is a validated diagnostic tool for the functional assessment of the young nervous system.

    Time frame: corrected 3 months of age

  5. Maternal depression

    The German long form of the Center for Epidemiological Studies Depression Scale (CES-D) will be used to assess maternal depression. The self-report questionnaire consists of 20 questions and its score ranges from 0 to 60. A score of 15 or higher indicates a risk of depression.

    Time frame: at the corrected age of 35-40 weeks' gestational age, at the corrected age of 6 months and at the corrected age of 24 months

  6. Post-traumatic Stress

    Post-traumatic stress is assessed with the impact of event scale - revised (IES-R). The self-report questionnaire consists of 22 questions and includes 3 sub-scales (intrusion, avoidance and hyperarousal). The overall score ranges from -4,36 to 2,99. A result above 0 is interpreted to indicate a risk of post-traumatic stress disorder.

    Time frame: at the corrected age of 6 months

  7. Parental Bonding

    Parental Bonding is assessed using the parental bonding questionnaire (PBQ), which consists of 25 items and includes 4 sub-scales (impaired bonding, rejection and anger, anxiety about care, risk of abuse). A higher the score indicates a higher risk of a disorder in each area of the sub-scale.

    Time frame: corrected age of 6 and 24 months

  8. Social Support

    Social support is assessed using the short version of the German questionnaire for social support (Fragebogen zur sozialen Unterstützung, questionnaire on social support) scale (F-SozU K-22). The questionnaire includes 22 items and its scale ranges from a minimum of 22 points to a maximum of 110 points. The higher the score, the better the subjectively perceived or anticipated support.

    Time frame: at the corrected age of 35-40 weeks' gestational age and at the corrected age of 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — As the participants in this study are minors, special attention will be paid to the protection of personal data. Therefore, the information and consent documents provided to the legal guardians contain a statement assuring that no data will be disclosed to third parties.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2036, 120 months later.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 120 months is above that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 24, 2026
StartEst.
Mar 13, 2026
Primary completionEst.
Mar 13, 2036
CompletionEst.
Mar 13, 2056
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07490912
Lead sponsor
University Hospital of Cologne
Responsible party
Charlotte Sophie Schömig (Dr. med., University Hospital of Cologne) — Principal investigator
First posted
Mar 24, 2026
Start date
Mar 13, 2026 (estimated)
Primary completion
Mar 13, 2036 (estimated)
Completion
Mar 13, 2056 (estimated)
Last update
Mar 24, 2026

Study contacts

Charlotte S Schömig, Dr. med.
Contact
charlotte.schoemig@uk-koeln.de
+49 221 478 85663
Angela Kribs, Apl. Prof. Dr.
Contact
angela.kribs@uk-koeln.de
+49 221 478 85663
Angela Kribs, Apl. Prof. Dr.
principal investigator · University Hospital Cologne
Miguel A Alejandre Alcázar, Prof. Dr.
principal investigator · University Hospital Cologne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion